GLP-1 drugs and skin disease: the evidence

GLP-1 receptor agonists were developed to lower blood sugar and body weight. Now dermatologists and metabolic medicine physicians are asking a different question: can the same drugs improve the skin conditions that so often travel alongside obesity and insulin resistance? A review published in Clinics in Dermatology in September 2026 by DeCoster and Narla examined the evidence for GLP-1 receptor agonists across four dermatologic areas: psoriasis, hidradenitis suppurativa, acne, and wound healing^[1]. The short answer is that the signal is real, particularly for inflammatory skin disease, but the controlled trial data are thin and most of the evidence comes from case series, small cohorts, and post-hoc analyses.

Which skin conditions appear on the research radar

Psoriasis and hidradenitis suppurativa (HS) are the two conditions with the most consistent signal. Both are chronic inflammatory diseases with well-documented metabolic comorbidities: obesity, insulin resistance, dyslipidaemia, and elevated C-reactive protein are common in patients with either condition. Because GLP-1 receptor agonists address multiple metabolic risk factors at once, researchers have theorised that any benefit might work through two parallel routes: weight reduction and a direct anti-inflammatory effect on immune pathways shared between metabolic disease and inflammatory skin disease^[1]. The DeCoster and Narla review frames these drugs as potential "immune-metabolic therapies" rather than simple weight-loss agents when applied to dermatology.

A 2026 review in Expert Review of Clinical Immunology by Ho and colleagues surveyed both the efficacy signals and the adverse-event profile for GLP-1 receptor agonists in dermatology^[2]. The authors found that small studies pointed to improvement in psoriasis and hidradenitis suppurativa, particularly with liraglutide, but that the available evidence was not yet sufficient to support routine clinical use. They also catalogued cutaneous adverse events from these agents, including hypersensitivity reactions, panniculitis, and alopecia, a side-effect profile the clinical community needs to weigh against any potential benefit.

Psoriasis and hidradenitis suppurativa: where the signal is strongest

For psoriasis, the existing data describe reduction in Psoriasis Area and Severity Index scores in patients treated with GLP-1 receptor agonists, largely in the context of studies designed to test metabolic outcomes rather than skin clearance specifically^[1]. The benefit appears to correlate partly with weight loss (greater weight reduction is associated with better psoriasis outcomes across multiple treatment classes) and partly with systemic anti-inflammatory effects that are weight-independent.

For hidradenitis suppurativa, the biology is suggestive: HS shares mechanistic overlap with metabolic syndrome, and excess adipose tissue drives elevated tumour necrosis factor-alpha and interleukin-1 beta, the same cytokines targeted by existing biologic therapies for HS. A JAAD CME article by Narla and Narla published in early 2026 summarised the early clinical evidence for GLP-1 receptor agonists in chronic inflammatory skin disease and concluded that the case reports and small cohorts are promising but that the field lacks adequately powered randomised trials^[3]. The article noted that gastrointestinal intolerance, biliary disease risk, and dermatologic adverse reactions (including drug eruptions and acne flares in a subset of patients) remain practical concerns for clinicians considering these agents.

What tirzepatide adds to the picture

Most of the early dermatology literature was built on older GLP-1 receptor agonists such as liraglutide and exenatide. The DeCoster and Narla review specifically notes that tirzepatide, a dual GIP and GLP-1 receptor agonist, has demonstrated enhanced skin clearance alongside substantial weight loss in cases of psoriasis, and is associated with a reduced risk of psoriatic arthritis, based on the data available to date^[1]. Tirzepatide's GIP receptor activity is absent from pure GLP-1 agonists such as semaglutide, and researchers have speculated that this additional receptor engagement may contribute differently to inflammation modulation. Whether the GIP component adds meaningful dermatologic benefit over and above the GLP-1 effect remains an open question.

Tirzepatide (marketed as Mounjaro for type-2 diabetes, authorised by the EMA and FDA for both diabetes and weight management) carries its own adverse-event profile that any dermatology clinician would need to review^[4]. The prescribing information includes gastrointestinal effects, thyroid C-cell tumour risk in rodents (clinical significance uncertain in humans), and a requirement to avoid use in patients with personal or family history of medullary thyroid carcinoma. None of the dermatology-specific studies reviewed by DeCoster and Narla were designed to evaluate these risks in skin-disease populations specifically. For background on tirzepatide's mechanism and regulatory status, see the tirzepatide peptide page.

Acne, wound healing, and other early signals

The DeCoster and Narla review covers acne and wound healing as areas with early or theoretical signal. For acne, the proposed mechanism runs through insulin resistance: hyperinsulinaemia drives IGF-1 activity, which in turn promotes sebum production and comedone formation. Reducing insulin resistance with a GLP-1 receptor agonist could, in theory, attenuate that pathway. The published data are confined to case reports and small series, and causality is not established^[1].

For wound healing, the interest is partly mechanistic: GLP-1 receptors are expressed in keratinocytes, and preclinical work has suggested that receptor activation may promote cell migration and collagen synthesis. Whether this translates to clinically meaningful wound-healing benefit in humans at doses used for metabolic disease is not yet known. The authors frame this as a promising area for future investigation rather than a current clinical application.

What the evidence does not yet tell us

The DeCoster and Narla review is clear about the limits of the current literature^[1]. No adequately powered randomised controlled trial has tested a GLP-1 receptor agonist as a primary treatment for any dermatologic condition. The studies in this space have typically enrolled patients with metabolic disease as the primary indication, measured skin outcomes as secondary endpoints, and followed patients for months rather than years. Long-term skin-disease remission data, dose-response relationships for dermatologic endpoints, and head-to-head comparisons with established dermatologic biologics do not yet exist.

The adverse-event signal is also incomplete. Ho et al. note that autoimmune skin reactions (including lupus-like presentations and vasculitis) have been reported with GLP-1 receptor agonists in pharmacovigilance databases, although causality is difficult to establish^[2]. A clinician prescribing one of these agents for a patient with pre-existing inflammatory skin disease would be managing a more complex risk-benefit calculation than the one described in the metabolic disease trial populations.

Medical disclaimer: this article is for educational and journalistic purposes only and does not constitute medical advice. GLP-1 receptor agonists are prescription medicines in all the jurisdictions covered on this site. Decisions about starting, adjusting, or stopping any medication should be made with a qualified clinician who knows your full medical history.